Literature DB >> 6974066

The human cytotoxic T cell response to influenza A vaccination.

A J McMichael, F Gotch, P Cullen, B Askonas, R G Webster.   

Abstract

The human cytotoxic T lymphocyte (CTL) response to challenge with influenza A vaccine was studied. Six of eight volunteers given killed whole influenza virus A/USSR (H1N1) vaccine showed substantial increases on the level of CTL memory 1 month after immunization. The CTL measured at this time showed complete cross-reactivity in their specificity for influenza A/USSR (H1N1) and A/X31 (H3N2) infected cells and also showed HLA restriction. The level of CTL memory increased in only three out of nine donors given subunit vaccine and showed no change in those not given vaccine. If cytotoxic T cells are important in influenza prophylaxis, killed whole virus vaccine should offer better protection than subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974066      PMCID: PMC1537292     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses.

Authors:  H J Zweerink; S A Courtneidge; J J Skehel; M J Crumpton; B A Askonas
Journal:  Nature       Date:  1977-05-26       Impact factor: 49.962

2.  Cytotoxic T cells in the lungs of mice infected with an influenza A virus.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

3.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

4.  Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes.

Authors:  T J Braciale
Journal:  Cell Immunol       Date:  1977-10       Impact factor: 4.868

5.  Influenza virus-specific cytotoxic T cells in man; induction and properties of the cytotoxic cell.

Authors:  A J McMichael; B A Askonas
Journal:  Eur J Immunol       Date:  1978-10       Impact factor: 5.532

6.  Influenza at Christ's Hospital: March, 1974.

Authors:  T W Hoskins; J R Davies; A J Smith; A Allchin; C L Miller; T M Pollock
Journal:  Lancet       Date:  1976-01-17       Impact factor: 79.321

7.  Antigenic drift and efficacy of influenza virus vaccines, 1976--1977.

Authors:  G Meiklejohn; T C Eickhoff; P Graves; J I
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

8.  Studies with inactivated influenza vaccines purified by zonal centrifugation. 2. Efficacy.

Authors:  S C Schoenbaum; S R Mostow; W R Dowdle; M T Coleman; H S Kaye
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

9.  Hemagglutinin-specific cytotoxic T-cell response during influenza infection.

Authors:  F A Ennis; W J Martin; M W Verbonitz
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

10.  HLA restriction of human cytotoxic T lymphocytes specific for influenza virus. Poor recognition of virus associated with HLA A2.

Authors:  A McMichael
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  31 in total

1.  Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Authors:  Otfried Kistner; M Keith Howard; Martin Spruth; Walter Wodal; Peter Brühl; Marijan Gerencer; Brian A Crowe; Helga Savidis-Dacho; Ian Livey; Manfred Reiter; Ines Mayerhofer; Christa Tauer; Leopold Grillberger; Wolfgang Mundt; Falko G Falkner; P Noel Barrett
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

2.  Immunity to influenza. Preventing infection and regulating disease.

Authors:  E Kaitlynn Allen; Paul G Thomas
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

3.  HLA-B27, a dominant restricting element in antiviral responses?

Authors:  E Gomard; M Sitbon; A Toubert; B Bègue; J P Lévy
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

Review 4.  Some newly recognized aspects of resistance against and recovery from influenza.

Authors:  A Ennis
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

6.  Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.

Authors:  Toshihiro Sawai; Yasushi Itoh; Hiroichi Ozaki; Norikazu Isoda; Kiyoko Okamoto; Yoshitaka Kashima; Yoshihiro Kawaoka; Yoshihiro Takeuchi; Hiroshi Kida; Kazumasa Ogasawara
Journal:  Immunology       Date:  2008-01-16       Impact factor: 7.397

Review 7.  Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.

Authors:  John S Oxford
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

8.  Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans.

Authors:  Douglas V Dolfi; Kathleen D Mansfield; Antonio M Polley; Susan A Doyle; Gordon J Freeman; Hanspeter Pircher; Kenneth E Schmader; E John Wherry
Journal:  J Leukoc Biol       Date:  2013-02-25       Impact factor: 4.962

Review 9.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

10.  H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.

Authors:  Xing Cheng; Michael Eisenbraun; Qi Xu; Helen Zhou; Deepali Kulkarni; Kanta Subbarao; George Kemble; Hong Jin
Journal:  PLoS One       Date:  2009-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.